Physician Materials

Mylan is committed to supporting Canadian physicians through education, patient materials, and risk management programs.

Clarus® CLEAR™ Program

Clarus® (isotretinoin capsules) is used to treat the most severe form of acne (nodular acne) that cannot be cleared up by any other acne treatments, including antibiotics. Providing information and support materials for Clarus® patients and healthcare professionals.

Gen-Clozapine Access Network (GenCAN)

Gen-Clozapine (clozapine tablets) is indicated in the management of symptoms of treatment-resistant schizophrenia. 

Demonstrating Mylan’s commitment to patient safety, GenCAN is a national network designed to assist physicians and pharmacists in the registering and monitoring of Gen-Clozapine patients.

Information for patients who have been prescribed Gen-Clozapine.


Mylan-Buprenorphine/Naloxone (M-BN) is part of a medical, social and psychological treatment program for adults undergoing substitution treatment for problematic opioid drug dependence.

The Buprenorphine and Naloxone Education Program (BNEP) is a risk management program that helps to ensure the safe and effective use of the drug. This program provides training for physicians, nurses, pharmacists and other healthcare professionals in the use of M-BN sublingual tablets.


Mylan-Bosentan is prescribed for the treatment of pulmonary arterial hypertension. Health Canada has deemed Mylan-Bosentan as bioequivalent to Tracleer®.


Campral® (acamprosate calcium delayed release tablets) is used to help alcohol dependent people abstain from drinking alcohol. Acamprosate acts centrally and appears to restore the normal balance between neuronal excitation and inhibition that becomes altered as a result of chronic alcohol exposure. Campral® should be used as part of a complete treatment program that includes counselling. 

Clozaril® is a product of HLS Therapeutics Inc.
Tracleer® is a product of Actelion Pharmaceuticals Ltd.